BUFY02

BUFY02 is an investigational ophthalmic product being developed by TRB Chemedica International for the treatment of dry eye disease. It is being evaluated in a randomized, double‑blind, active‑controlled, non‑inferiority trial versus TRB02 (study BUFY02-CT-2201; BUSTON‑02) in adults with dry eye disease, with participants using study eye drops daily for approximately three months.[1][10][13][14] Publicly available clinical-trial registry and pipeline listings describe the study design and indication but do not disclose BUFY02’s active ingredient, formulation, or precise mechanism of action, and it remains in early clinical development with no marketing authorization.